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SUMMARY 
Metabolic regulation influences cell proliferation. The influence of pyruvate kinase 
isoforms on tumor cells has been extensively studied, but whether PKM2 is required for 
normal cell proliferation is unknown. We examine how PKM2-deletion affects 
proliferation and metabolism in non-transformed, non-immortalized PKM2-expressing 
primary cells. We find that deletion of PKM2 in primary cells results in PKM1 expression 
and proliferation arrest. PKM1 expression, rather than PKM2 loss, is responsible for this 
effect, and proliferation arrest cannot be explained by cell differentiation, senescence, 
death, changes in gene expression, or prevention of cell growth. Instead, PKM1 
expression impairs nucleotide production and the ability to synthesize DNA and 
progress through the cell cycle. Nucleotide biosynthesis is limiting, as proliferation arrest 
is characterized by severe thymidine depletion, and supplying exogenous thymine 
rescues both nucleotide levels and cell proliferation. Thus, PKM1 expression promotes 
a metabolic state that is unable to support DNA synthesis.  
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INTRODUCTION 
Proliferating cells metabolize glucose via aerobic glycolysis (Cairns et al., 2011; 
Hanahan and Weinberg, 2011; Koppenol et al., 2011). Aerobic glycolysis is 
characterized by increased glucose uptake and lactate excretion in the presence of 
oxygen, and has been proposed to promote the use of glucose for biosynthetic 
pathways necessary for cell growth and division (Lunt and Vander Heiden, 2011; Ward 
and Thompson, 2012); however, connections between aerobic glycolysis and specific 
pathway use are not well defined. The M2 isoform of the glycolytic enzyme pyruvate 
kinase (PKM2) has been associated with both aerobic glycolysis and anabolic 
metabolism in cancer cells (Anastasiou et al., 2012; Christofk et al., 2008a; Mazurek, 
2011). PKM2 is also expressed in normal proliferating tissues (Mazurek, 2011); yet how 
pyruvate kinase isoform expression influences cell metabolism to support proliferation, 
and whether PKM2 is required for normal cell proliferation is unclear.  
Pyruvate kinase converts phosphoenolpyruvate and ADP to pyruvate and ATP in 
glycolysis. Four isoforms of pyruvate kinase exist in mammals; each with varying kinetic 
and regulatory properties adapted for different tissue types. The PKLR gene uses two 
different promoters with alternative first exons to produce either the R isoform found in 
red blood cells, or the L isoform expressed in gluconeogenic tissues such as the liver 
and kidney (Domingo et al., 1992; Noguchi et al., 1987). The M1 and M2 isoforms are 
produced by mutually exclusive alternative mRNA splicing of the PKM gene. Including 
exon 9 in the transcript generates PKM1, while including exon 10 generates PKM2 
(Noguchi et al., 1986; Yamada and Noguchi, 1999). PKM2 is found in early embryonic 
cells, normal proliferating cells, and tumor cells, as well as in white fat, lung, retina, and 
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pancreatic islets (Imamura and Tanaka, 1982; Mazurek, 2011). PKM1 replaces PKM2 
during development in tissues with high ATP production requirements including skeletal 
muscle, heart, and brain (Imamura et al., 1986; Mazurek, 2011). When cell proliferation 
is reactivated in non-proliferating tissues that do not express PKM2, such as during liver 
regeneration or carcinogenesis, PKM2 expression is observed (Hacker et al., 1998; 
Steinberg et al., 1999; Van Veelen et al., 1977; Yamada and Noguchi, 1995), implying 
PKM2 may be important for proliferation. 
PKM1 and PKM2 exhibit different regulatory and catalytic properties. PKM1 is not 
allosterically regulated and assembles into stable homotetramers with high pyruvate 
kinase activity (Gui et al., 2013; Mazurek, 2011). In contrast, PKM2 can exist in an 
inactive non-tetrameric form or active tetrameric form, and these states can be 
regulated by phosphotyrosine signaling, redox status, acetylation, and metabolic 
intermediates including FBP, amino acids, SAICAR, and fatty acids (Anastasiou et al., 
2011; Anastasiou et al., 2012; Chaneton et al., 2012; Christofk et al., 2008b; Keller et 
al., 2012; Lv et al., 2011). In addition, several non-glycolytic functions specific for PKM2 
have been reported to be critical for cancer cell proliferation (Gao et al., 2012; Jiang et 
al., 2014; Keller et al., 2014; Luo et al., 2011; Yang et al., 2012a; Yang et al., 2011; 
Yang et al., 2012b), but it is unclear if any of these functions are important for 
proliferation of normal cells. 
Here, we use non-immortalized primary cells from PKM2-conditional mice to 
study the role of PKM1 and PKM2 isoform expression in cell metabolism and 
proliferation. Deletion of PKM2 in these cells results in PKM1 expression and 
proliferation arrest. Expression of PKM1 in cells that co-express PKM2 also results in 
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proliferation arrest, suggesting that expression of PKM1, rather than loss of PKM2, is 
responsible for this phenotype. Proliferation arrest is not associated with cell 
differentiation, senescence, changes in gene expression, or death; instead, PKM1 
expression results in decreased flux to select biosynthetic pathways with nucleotide 
synthesis being a critical pathway that is limiting for cell proliferation. Proliferation arrest 
can be rescued by exogenous pyrimidine or purine base supplementation. These data 
argue that PKM1 expression suppresses nucleotide biosynthesis, and that PKM2 
expression supports flux into metabolic pathways to support DNA synthesis.  
 
RESULTS 
PKM1 expression causes proliferation arrest of primary embryonic fibroblasts 
To study the role of PKM2 in cell proliferation, we derived embryonic fibroblasts 
(MEFs) from mice where LoxP sites flank PKM2-specific exon 10 (PKM2fl/fl) and harbor 
an inducible Cre recombinase allele (Cre-ER) (Israelsen et al., 2013). Deletion of exon 
10 disrupts the ability of cells to produce PKM2 or any truncated protein product with 
PKM2 activity, but does not prevent production of PKM1 (Israelsen et al., 2013). When 
Cre recombinase remains inactive, PKM2 is expressed in PKM2fl/fl Cre-ER cells (Figure 
1A), as reported for wildtype MEFs (Anastasiou et al., 2011). Addition of 4-
hydroxytamoxifen (4-OHT) activates Cre recombinase, leading to loss of PKM2 protein 
and PKM1 expression (Figure 1A). PKM1 expression is observed one day after 4-OHT 
treatment; however, residual PKM2 can be detected for up to 4 days following 4-OHT 
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treatment, presumably due to the half-life of PK protein being as long as 104 hours (Illg 
and Pette, 1979; Yee et al., 2010).  
Similar to wildtype MEFs, primary PKM2fl/fl Cre-ER MEFs proliferate rapidly in 
culture for multiple passages (Figure 1B). When treated with 4-OHT, these MEFs exhibit 
a marked decrease in proliferation (Figure 1B). A similar proliferation arrest was 
observed in multiple lines, each independently derived from different PKM2fl/fl Cre-ER 
mice (Figure S1A). To ensure that 4-OHT treatment itself is not affecting PK isoform 
expression or cell proliferation, we generated MEFs from PKM2fl/fl mice that do not 
harbor a Cre-ER allele. These Cre-negative PKM2fl/fl MEFs express PKM2 (Figure S1B) 
and proliferate at a similar rate regardless of 4-OHT treatment (Figure 1C).  
To determine whether expression of PKM1 or loss of PKM2 is responsible for cell 
proliferation arrest, we derived MEFs from PKM2fl/+ Cre-ER mice. Without 4-OHT 
treatment, these MEFs express only PKM2 (Figure 1D) and proliferate for several 
passages (Figure 1E). 4-OHT treatment of PKM2fl/+ Cre-ER MEFs causes deletion of 
the PKM2 conditional allele and results in expression of PKM1 with continued PKM2 
expression from the wildtype allele (Figure 1D). As observed in PKM2fl/fl Cre-ER MEFs, 
4-OHT addition caused a similar proliferation arrest in PKM2fl/+ Cre-ER MEFs despite 
retention of PKM2 expression (Figure 1E). Cre expression alone can also slow 
proliferation without affecting pyruvate kinase isoform expression, but does not increase 
J-H2AX levels and has less impact on cell proliferation than Cre-mediated PKM2 
deletion (Figure S1C-S1E). To test whether the increase in pyruvate kinase activity 
associated with gain of PKM1 expression contributes to a block in proliferation, we 
monitored proliferation of wildtype MEFs following addition of the small molecule PKM2 
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activator TEPP-46 (Anastasiou et al., 2012). TEPP-46 decreases proliferation (Figure 
1F), and exogenous PKM1 cDNA expression also reduces proliferation of wildtype 
MEFs (Figure S1F). Together, these data suggest proliferation is suppressed in 
PKM2Δ/Δ MEFs due to gain of PKM1 rather than loss of PKM2. 
 
Deletion of PKM2 does not induce cell death, senescence, or differentiation 
Potential explanations for why PKM1 expression suppresses proliferation include 
an increase in cell death, cell senescence, and/or differentiation to a non-proliferating 
cell population. To begin to examine these possibilities in cells with and without PKM2 
deletion, we quantified the percentage of viable cells by propidium iodide exclusion and 
the amount of cell death by lactate dehydrogenase release (Decker and Lohmann-
Matthes, 1988; Nicoletti et al., 1991). No difference in cell viability or LDH release was 
found between PKM2fl/fl and PKM2Δ/Δ MEFs as late as 9 days after vehicle or 4-OHT 
treatment despite a large difference in cell number (Figures 2A and S2A). Consistent 
with these results, >90% of MEFs from both populations exclude trypan blue at this time 
point. These data suggest PKM1 expression following PKM2-deletion inhibits cell 
proliferation without increasing cell death. 
Primary MEFs undergo senescence upon serial passage in culture that involves 
entry into a state of irreversible proliferation arrest (Campisi, 2011; Kuilman et al., 2010; 
Odell et al., 2010). Therefore, it was possible that PKM1 expression induces early 
senescence. One marker of senescent cells is acid-stable  β-galactosidase activity 
(Castro et al., 2003; Dimri et al., 1995; van der Loo et al., 1998). No difference in acid-
stable  β-galactosidase activity was found between early passage proliferating PKM2fl/fl 
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and proliferation-arrested PKM2Δ/Δ MEFs as late as 9 days after treatment with vehicle 
or 4-OHT (Figure 2B, upper panels). Late passage PKM2fl/fl MEFs senesce as 
evidenced by proliferation arrest, morphology change, and acid-stable  β-galactosidase 
staining. Surprisingly, despite no proliferation for days, PKM2Δ/Δ MEFs stain positive for 
acid-stable  β-galactosidase activity at the same time PKM2fl/fl MEFs senesce due to 
high passage number (Figure 2B, lower panels). These data suggest induction of the 
senescence program observed with serial primary cell passage does not correlate with 
proliferation arrest of PKM2Δ/Δ cells. 
Primary MEFs can differentiate under specific culture conditions. For instance, 
MEFs can differentiate along an adipocyte-like lineage and accumulate neutral lipids 
(Green and Kehinde, 1974; Russell and Ho, 1976). To determine if PKM2Δ/Δ MEFs 
accumulate lipids, we stained them with Oil Red O and found no evidence of lipid 
accumulation (Figure S2B). To further test whether PKM2 deletion causes 
differentiation, and determine whether proliferation arrest is observed in PKM2Δ/Δ 
primary cells other than MEFs, we isolated myoblasts from PKM2fl/fl Cre-ER mice. 
Myoblasts can be induced to differentiate into myotubes with characteristic morphology 
(Wakelam, 1985), and are a well-studied differentiation model (Abmayr and Pavlath, 
2012). Similar to the phenotype observed in PKM2fl/fl Cre-ER MEFs, treatment of 
PKM2fl/fl Cre-ER myoblasts with 4-OHT results in PKM2 deletion and PKM1 expression 
(Figure S2C) with proliferation arrest (Figure 2C). Similar to immortalized C2C12 
myoblasts (Clower et al., 2010), we confirmed primary PKM2fl/fl Cre-ER myoblasts are 
capable of differentiation under conditions that favor myotube formation (Figure 2D) and 
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express PKM1 upon differentiation (Figure S2D). However, PKM2 deletion in myoblasts 
does not cause differentiation into myotubes (Figure 2D).  
 
PKM2Δ/Δ MEFs do not incorporate EdU 
 Lack of PKM2Δ/Δ MEF proliferation implies an inability to proceed through the cell 
cycle. To investigate whether PKM2Δ/Δ MEFs replicate DNA, they were incubated with 
EdU, a thymidine analog incorporated into DNA during S phase of the cell cycle. 
Consistent with lack of DNA synthesis, PKM2Δ/Δ MEFs exhibit decreased EdU 
incorporation compared to PKM2fl/fl MEFs (Figure 2E). Cells deprived of nutrients 
classically arrest in G1 phase of the cell cycle (Bohnsack and Hirschi, 2004). To 
determine whether PKM2Δ/Δ MEFs were arrested in G1, we analyzed DNA content by 
flow cytometry. Both the G1 and G2/M phase DNA content peaks widened in a pattern 
that is most consistent with more cells in S phase (Figure 2F). Dual staining of EdU 
incorporation and DNA content is also consistent with an inability to progress through 
the cell cycle, as less EdU incorporation is observed at all DNA contents, with much of 
the population having a DNA content between 2N and 4N despite no EdU uptake 
(Figure 2G). To compare PKM2Δ/Δ MEF arrest to cell cycle arrest induced by nutrient 
withdrawal, the DNA content of wildtype MEFs was assessed following removal of the 
essential amino acid lysine. Lysine withdrawal also causes proliferation arrest (Figure 
S2E); however, unlike PKM2Δ/Δ MEFs, these cells accumulate in G1 (Figures S2F). 
Taken together, these results argue that lack of proliferation caused by PKM1 
expression is distinct from G1 arrest caused by nutrient deprivation. Instead, these data 
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are more consistent with a failure of PKM2Δ/Δ MEFs to incorporate nucleotides into 
DNA.  
 
Despite proliferation arrest, PKM2Δ/Δ MEFs continue to uptake nutrients and grow 
Cell division can depend on cell size in eukaryotic cells (Johnston et al., 1977; 
Montagne et al., 1999). A possible explanation for why cells stop proliferating is that 
changes in metabolism lead to insufficient metabolic precursors to support cell growth, 
and sufficient size to complete a cell cycle is not achieved. To determine whether 
proliferation arrest of PKM2Δ/Δ MEFs is associated with decreased aerobic glycolysis, 
we measured consumption of glucose as well as lactate excretion. Surprisingly, despite 
proliferation arrest, PKM2Δ/Δ MEFs have higher glucose uptake and lactate excretion 
rates than PKM2fl/fl MEFs (Figures 3A and 3B). Overall glucose oxidation is also 
increased in PKM2Δ/Δ MEFs: measurement of 14CO2 production from uniformly 
radiolabeled glucose revealed ~40% more 14CO2 production from glucose over 24-hours 
in PKM2Δ/Δ MEFs than in PKM2fl/fl MEFs (Figure 3C). In addition, assessment of cell 
volume showed that PKM2Δ/Δ cells are ~1.7 times larger than proliferating PKM2fl/fl cells 
(Figure 3D). In fact, the mean volume of arrested PKM2Δ/Δ cells was larger than 85% of 
cycling PKM2fl/fl cells, suggesting PKM2Δ/Δ MEFs grow to a large size despite 
proliferation arrest. The cell volume increase is accompanied by increased protein 
amount, with total protein content of PKM2Δ/Δ MEFs ~1.9 times greater than total protein 
content in cycling PKM2fl/fl MEFs (Figure 3E). PKM2Δ/Δ MEFs also contain higher levels 
of fatty acids, with pool sizes of palmitate, oleate, and sterate > 2-fold higher in PKM2Δ/Δ 
MEFs compared to PKM2fl/fl MEFs (Figure S3). To confirm that increases in cell volume, 
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total protein, and select fatty acids are accompanied by an increase in cell mass, we 
utilized a suspended microchannel resonator (Burg et al., 2007) to determine dry mass 
at the single cell level (Feijo Delgado et al., 2013). The dry mass of PKM2Δ/Δ cells is 
greater than the dry mass of PKM2fl/fl cells (783 pg for PKM2Δ/Δ MEFs compared to 455 
pg for PKM2fl/fl MEFs; Figure 3F). One million PKM2Δ/Δ MEFs also weighed 24 ± 4% 
more than the same number of PKM2fl/fl MEFs when dried on filter paper and weighed 
using an analytical balance. Together, these data suggest that despite proliferation 
arrest, PKM2Δ/Δ MEFs continue to metabolize glucose at high rates and grow to a larger 
size than proliferating PKM2fl/fl MEFs.  
 
PKM2 supports specific aspects of anabolic metabolism 
Despite growing to a larger size, specific metabolite(s) or metabolic flux 
limitations could account for the inability of PKM2Δ/Δ cells to proliferate. To explore this 
hypothesis, we used isotope labeled nutrients and mass spectrometry-based metabolite 
analysis to probe metabolism of PKM2Δ/Δ MEFs in comparison to PKM2fl/fl MEFs. 
Analysis of intracellular metabolites after culture in the presence of uniformly labeled 
13C-glucose ([U-13C6]glucose) and glutamine ([U-13C5]glutamine) reveals that PKM2Δ/Δ 
MEFs have decreased labeling from glucose and glutamine in some biosynthetic 
precursors including the nucleotide uridine monophosphate (UMP) and the fatty acid 
palmitate (Figures 4 and S4). Moreover, 13C-glucose incorporation into serine and 
glycine were also decreased in PKM2Δ/Δ MEFs. In contrast, a higher percentage of TCA 
cycle intermediates are labeled from [U-13C6]glucose in PKM2Δ/Δ MEFs (Figure 4A), 
suggesting increased glucose contribution and/or decreased glutamine contribution to 
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the TCA cycle. Labeling studies using [U-13C5]glutamine show that PKM2Δ/Δ MEFs have 
lower glutamine contribution to TCA cycle intermediates (Figure 4B), implying that 
proliferation-arrested PKM2Δ/Δ MEFs rely more on glucose than glutamine to support the 
TCA cycle. These results confirm that PKM1 expression leads to increased glucose 
catabolism, and support a model where PKM1 expression curtails the use of glucose 
and glutamine for production of some biosynthetic precursors.  
Glucose is the major precursor for de novo palmitate synthesis in both PKM2Δ/Δ 
and PKM2fl/fl MEFs, despite less palmitate synthesized from both glucose and glutamine 
in PKM2Δ/Δ MEFs relative to PKM2fl/fl MEFs (Figure S4). The rate of total fatty acid 
synthesis decreased by 22% with PKM2 deletion in these cells, consistent with 
decreased lipid synthesis observed previously upon PKM1 expression (Anastasiou et 
al., 2012). A fraction of palmitate is produced from glutamine in PKM2fl/fl and PKM2Δ/Δ 
MEFs, with a labeling pattern consistent with synthesis by reductive metabolism in both 
cases (Fendt et al., 2013b; Metallo et al., 2012). Although PKM2Δ/Δ MEFs exhibit 
decreased fatty acid synthesis, they contain higher levels of intracellular fatty acids 
compared to their PKM2fl/fl counterparts (Figure S3). To accumulate high levels of fatty 
acids despite a decrease in biosynthesis, it is likely that PKM2Δ/Δ MEFs import 
exogenous fatty acids. Lipid scavenging from the media has been observed previously 
in cancer cells (Kamphorst et al., 2013). 
 
Proliferation of PKM2Δ/Δ MEFs is limited by nucleotides 
Pool sizes of intracellular metabolites were measured to assess whether specific 
metabolites are limiting for cell proliferation in PKM2Δ/Δ MEFs. While levels of most 
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metabolites in PKM2Δ/Δ cells were unchanged or increased relative to PKM2fl/fl cells 
(Figure S5A), nucleotide levels were lower, and the most depleted intracellular 
metabolite measured in PKM2Δ/Δ MEFs is thymidine monophosphate (dTMP; Figure 
5A). This is consistent with decreased glucose and glutamine contribution to UMP 
observed in PKM2Δ/Δ MEFs (Figure 4), as UMP is a biosynthetic precursor of dTMP.  
To explore the possibility that de novo nucleotide synthesis is decreased in 
PKM2Δ/Δ MEFs, we performed dynamic labeling experiments and flux modeling. 
Dynamic labeling with uniformly labeled 13C-glucose and 13C-glutamine confirms 
decreased glucose and glutamine flux to UMP in PKM2Δ/Δ MEFs (Figure 5B). The same 
labeling studies also suggest flux of glucose carbon into IMP and AMP is decreased 
slightly in PKM2Δ/Δ MEFs, while glutamine labeling is not informative as this amino acid 
does not contribute carbons to de novo purine synthesis. Analysis of metabolic fluxes 
from steady state labeling data (Antoniewicz et al., 2007; Young et al., 2008) support 
the notion that de novo nucleotide synthesis, glutamine to glutamate conversion, and 3-
phosphoglycerate (3PG) to serine flux are decreased in PKM2Δ/Δ MEFs (Figure 5C). 
Decreased 3PG to serine flux is consistent with previous reports of PKM2 expression 
shunting carbon into serine biosynthesis (Chaneton et al., 2012); however, despite 
decreased serine synthesis, serine levels remained unchanged (Figure S5A). To 
determine if serine metabolism could be limiting for de novo nucleotide biosynthesis, we 
modeled fluxes for serine-glycine-one carbon metabolism based on 13C-glucose 
incorporation into serine and glycine as well as serine and glycine uptake rates from the 
media (Figure S5B, Supplementary Material). While decreased 3PG conversion to 
serine was suggested by the model in PKM2Δ/Δ MEFs, serine uptake appeared sufficient 
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to compensate for any decrease in de novo serine synthesis, suggesting that a lack of 
serine availability alone is unlikely to account for impaired nucleotide synthesis.  
 
Proliferation arrest of PKM2Δ/Δ MEFs is not caused by gene expression changes 
We performed genome-scale gene expression analysis to explore whether 
changes in gene expression cause PKM2Δ/Δ MEFs proliferation arrest. Analysis of 
microarray data for PKM2Δ/Δ and PKM2fl/fl cells obtained from two different 
independently derived MEF lines revealed no correlation between gene expression 
changes and pyruvate kinase isoform expression (Figure 6A). In fact, unsupervised 
hierarchical clustering results in clustering by the embryo from which the MEFs were 
generated rather than by pyruvate kinase isoform expression. As an additional 
approach, we used fold change analysis to compare gene expression differences 
between PKM2Δ/Δ and PKM2fl/fl MEFs. This analysis revealed a small number of genes 
that show differences according to pyruvate kinase isoform expression, and these 
results were confirmed by RT-PCR (Figure S6A); however, none of the genes are 
directly related to metabolism or cell cycle control.  
Since metabolic analysis of PKM2Δ/Δ and PKM2fl/fl MEFs revealed deficiencies in 
nucleotide metabolism, we re-analyzed the gene expression data examining only 
nucleotide metabolism genes (Figure 6B). Again, unsupervised hierarchical clustering 
does not show a correlation between expression changes and pyruvate kinase isoform 
expression, and most genes show minimal change in expression levels. To confirm 
these results, we examined relative protein and gene expression levels of several key 
nucleotide metabolism genes by Western blotting and RT-PCR (Figures S6B and S6C).  
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None showed differences in expression between PKM2Δ/Δ and PKM2fl/fl MEFs. These 
results argue that changes in gene expression do not account for either impaired 
nucleotide synthesis or proliferation arrest of PKM2Δ/Δ MEFs. 
 
PKM2Δ/Δ MEFs cannot complete DNA synthesis 
To determine whether de novo pyrimidine production is limiting for proliferation of 
PKM2Δ/Δ MEFs, we attempted to prevent proliferation arrest by supplementing the 
media with thymine at the time of 4-OHT addition. Thymine supplementation prevented 
proliferation arrest of PKM2Δ/Δ MEFs (Figure 7A). Thymine supplementation also 
prevents depletion of intracellular dTMP and dTTP levels, as well as levels of other 
nucleotides (Figure 5A) and some other depleted metabolites (Figure S5A), but has no 
effect on proliferation of PKM2fl/fl MEFs or Cre expressing MEFs (Figures S7A and 
S1C). The ability of thymine supplementation to sustain proliferation of PKM2Δ/Δ MEFs 
is maintained for up to 10 days, and does not increase PKM2Δ/Δ MEF cell number by 
inducing a burst of proliferation following addition of thymine. The pyrimidines cytosine 
and uracil and purines inosine, guanine, and adenine also partially prevent proliferation 
arrest of PKM2Δ/Δ MEFs, but to a lesser extent (Figure 7A). To confirm that changes in 
serine are not limiting for cell proliferation, we supplemented PKM2Δ/Δ MEFs with serine; 
however, neither serine nor other substrates used in nucleotide synthesis rescued 
proliferation (Figure 7A).  
To determine whether thymine supplementation can restore proliferation of 
arrested PKM2Δ/Δ MEFs, we added thymine to the media 5 days after 4-OHT addition, a 
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time point when PKM2-deleted cells have stopped proliferating (Figure 1B). Thymine 
addition restores proliferation that is sustained for several days; however, the cells 
senesce around day 10 and thus undergo fewer population doublings (Figure S7B). 
Even when media is changed every 3 days without replating, no spontaneous recovery 
has been observed in PKM2Δ/Δ MEFs despite following cultures for up to 18 days after 
proliferation arrest.  
 To determine whether DNA synthesis might be limited by nucleotide pools in 
PKM2Δ/Δ MEFs, we performed DNA labeling studies to directly visualize nucleotide 
incorporation into DNA over time (Figure 7B). While PKM2fl/fl MEFs incorporate both 5-
Chloro-2′-deoxyuridine (CldU) and 5-Iodo-2′-deoxyuridine (IdU) to produce long DNA 
strands over a 20 minute period, PKM2Δ/Δ MEFs are only able to incorporate CldU and 
IdU for short bursts, and strands with both CldU and IdU are rarely observed (Figures 
7B and 7C). These data suggest at least some PKM2Δ/Δ MEFs are in S phase because 
limited CldU and IdU incorporation into DNA is observed. The data also argue that 
PKM2Δ/Δ MEFs are unable to sustain DNA synthesis, and are consistent with nucleotide 
depletion causing proliferation arrest. Together, our experiments argue PKM1 
expression leads to low nucleotide levels and an inability to replicate DNA. 
 
DISCUSSION 
While most proliferating cells express PKM2, the exact role of PKM2 in cell 
proliferation remains controversial. Unlike constitutively active PKM1, PKM2 can be 
regulated to assume either a low or high activity state, and the inactive state of PKM2 is 
favored in proliferating tumor cells (Israelsen et al., 2013). It has been proposed that 
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less active PKM2 allows buildup of upstream glycolytic metabolites that can feed into 
biosynthetic pathways, with the subsequent ability to use these metabolites for anabolic 
metabolism (Christofk et al., 2008b; Eigenbrodt and Glossmann, 1980). Consistent with 
this idea, our data show that expression of constitutively active PKM1 results in 
decreased de novo nucleotide biosynthesis. However, contrary to this hypothesis, 
PKM1 expression did not deplete upstream glycolytic intermediates or impair all 
anabolic metabolism. Instead, pools of upstream glycolytic intermediates and most 
intracellular metabolites were unchanged, and the cells continued to accumulate protein 
and lipids to grow to a larger size. This suggests protein and nucleotide synthesis can 
be uncoupled in these cells. This is in contrast to findings in some cancer cells where 
coordinate regulation of protein synthesis and nucleotide synthesis is observed 
(Cunningham et al., 2014) 
PKM1 expression led to severe thymidine depletion and proliferation arrest that is 
rescued by thymine supplementation. Although all nucleotides were depleted, depletion 
of pyrimidines may be most severe because they depend on both glucose and 
glutamine as carbon sources, while purines only depend on glucose. Thymine 
supplementation was most effective; however, supplementation of other nucleotide 
bases could also partially prevent proliferation arrest. Nucleotide levels in cells are 
tightly regulated with complex allosteric control of synthesis maintaining balanced pools 
in cells such that changes in one nucleotide pool can impact the availability of other 
nucleotides (Cohen et al., 1983; Reichard, 1988). Although pyrimidines and purines 
cannot be interconverted, changes in pyrimidine production impacts both purine and 
pyrimidine levels (Reaves et al., 2013). Methotrexate impairs thymidine synthesis and 
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depletes both purines and pyrimidines in tumor cells (Hryniuk, 1975; Hryniuk et al., 
1975; Tattersall et al., 1974).  Thymidine supplementation alone rescues methotrexate 
toxicity in some cancer cells, while others require both purine and pyrimidine 
supplementation (Harrap et al., 1977).   
Thymidine depletion is the basis for anti-proliferative therapies that range from 
antibiotics (Hawser et al., 2006; Kwon et al., 2010) to cancer chemotherapy (Gangjee et 
al., 2007; Witherspoon et al., 2013). The success of drugs that target thymidine pools 
highlights the importance of generating this nucleotide in proliferating cells. Nucleotide 
depletion can trigger cell cycle arrest in human neuroblastoma cell lines (Messina et al., 
2004) and T lymphocytes (Laliberté et al., 1998). Similar to our findings, proliferation 
arrest induced by nucleotide depletion in T lymphocytes could be reversed with 
nucleotide supplementation (Turka et al., 1991). Accumulation of cells in S phase and a 
slow DNA replication rate has also been observed in cells treated with hydroxyurea, a 
ribonucleotide reductase inhibitor that lowers deoxynucleotide pools (Anglana et al., 
2003). Additional studies have shown low nucleotides can impair cancer progression 
(Cunningham et al., 2014) or cause oncogene-induced senescence (Aird et al., 2013), 
suggesting nucleotide levels can limit proliferation in other contexts.   
Some mammalian cells can continue DNA synthesis with imbalanced 
deoxyribonucleoside pools (Meuth, 1989); however, nucleotide insufficiency can also 
result in DNA polymerase stalling, collapsed replication forks, and activation of the DNA 
damage response (Bester et al., 2011). Activation of the DNA damage response is one 
mechanism that could account for S-phase cell cycle arrest in PKM2Δ/Δ cells, although 
increased J-H2AX staining was not observed. The lack of sustained DNA replication in 
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PKM2Δ/Δ cells suggests they enter S-phase with insufficient nucleotides to complete this 
phase of the cell cycle. It has been suggested that one function of the G1-S cell size 
check point is to ensure sufficient nutrients are available to complete S-phase (Foster et 
al., 2010), while others have argued that mammalian cells only have sufficient precursor 
stores to sustain DNA replication for a few minutes and therefore must continuously 
replenish deoxynucleotide pools to replicate the genome (Reichard, 1988). These data 
argue that regulation of pyruvate kinase isoform expression can impact the ability of 
cells to generate nucleotides and progress through S-phase.  
To avoid a high mutation rate, cells may decrease oxidative metabolism during 
S-phase to protect the genome from DNA damage (Tu et al., 2005). PKM2 expression 
can favor the use of aerobic glycolysis (Christofk et al., 2008a); however, apart from 
protecting the genome by limiting oxidative phosphorylation, these data imply that 
aerobic glycolysis may also be important for supporting nucleotide synthesis to 
complete S-phase. Supporting nucleotide production may be another mechanism by 
which aerobic glycolysis keeps the mutation rate low by preventing collapsed replication 
forks caused by insufficient nucleotides. 
Serine activates PKM2 and decreases new serine synthesis (Chaneton et al., 
2012). Increased pyruvate kinase activity from PKM1 expression decreases 3PG to 
serine flux; however, serine levels are not affected in these cells despite decreased 
serine production. In fact, serine levels are maintained despite increased protein and 
cell mass in PKM2Δ/Δ relative to PKM2fl/fl MEFs.  
Non-metabolic functions of PKM2 have also been reported (Gao et al., 2012; 
Keller et al., 2014; Luo et al., 2011; Yang et al., 2012a; Yang et al., 2011; Yang et al., 
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2012b), including a role for PKM2 in regulating mitosis (Jiang et al., 2014). However, the 
failure of most PKM2Δ/Δ MEFs to arrest in G2/M, and the ability to rescue proliferation 
with thymine supplementation both argue defects in chromosome segregation are not a 
major cause of proliferation arrest in these cells. Because most non-metabolic PKM2 
functions are proposed to alter gene expression, the observation that loss of PKM2 
causes minimal gene expression changes suggests that these PKM2 activities are less 
active in primary MEFs. 
 The inability of PKM2Δ/Δ MEFs to sustain DNA synthesis is consistent with a 
model where a switch from PKM2 to PKM1 expression leads to low deoxynucleotide 
levels, an inability to replicate DNA, and decreased proliferation without affecting cell 
mass accumulation. How pyruvate kinase activity regulates nucleotide biosynthesis 
remains unknown. PKM2 can influence ribose production via the oxidative pentose 
phosphate pathway in cancer cells (Anastasiou et al., 2011), but altered ribose 
production was not observed in PKM2Δ/Δ MEFs. Regardless of how pyruvate kinase 
influences nucleotide synthesis, these findings support the notion that independent of 
nutrient uptake, how nutrients are metabolized determines whether cells engage in 
proliferation. 
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EXPERIMENTAL PROCEDURES 
All mouse studies were performed in accordance with institutional guidelines and 
approved by the MIT Committee on Animal Care. 
 
Isolation and culture of primary mouse embryonic fibroblasts  
Primary mouse embryonic fibroblasts (MEFs) were isolated and cultured using 
published methods (Springer et al., 2001). Embryos were isolated at E11.5 – E14.5 of 
gestation, and each embryo processed separately. MEFs were cultured in MEF medium 
(Dulbecco’s  Modified  Eagle’s  Medium  with  10%  heat  inactivated  FBS,  1%  
streptomycin/penicillin, 1 mM glutamine, and 0.1 mM 2-mercaptoethanol) and plated at 
a density of 5 × 106 cells per 10 cm plate. Cells were split before reaching confluence 
and replated at 750,000 cells per 10 cm plate. 1 µM 4-hydroxytamoxifen in ethanol was 
used to induce recombination of PKM2fl alleles. Cells starved of lysine were incubated 
in lysine-free DMEM and doubling time analyzed over 10 days. 
 
Cell proliferation analysis 
750,000 cells were seeded in triplicate in 10 cm plates, and cell counts obtained using a 
Cellometer Auto T4 Cell Counter (Nexcelom). Cells were replated at 70% confluence, 
counted, and reseeded at a density of 750,000 per 10 cm plate. Population doubling 
(PD) was calculated using the following formula:  
𝑃𝐷 =   
௟௢௚ቀ೙ೠ೘್೐ೝ  ೚೑  ೎೐೗೗ೞ  ೎೚ೠ೙೟೐೏
೙ೠ೘್೐ೝ  ೚೑  ೎೐೗೗ೞ  ೞ೐೐೏೐೏
ቁ
௟௢௚(ଶ)
+ 𝑝𝑟𝑒𝑣𝑖𝑜𝑢𝑠  𝑃𝐷. 
When used, all metabolite supplements were added to MEF medium at a concentration 
of 250 µM.  
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Metabolite uptake and excretion 
Conditioned medium was sampled after 72 h. Levels of glucose and lactate were 
measured using YSI 7100 Select Biochemistry Analyzer. The following equation was 
used to calculate metabolite consumption/excretion per 106 cells per hour (α): 
 
 
α =
[𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]௜௡௜௧௜௔௟ − [𝑚𝑒𝑡𝑎𝑏𝑜𝑙𝑖𝑡𝑒]௙௜௡௔௟
𝑋௜௡௜௧௜௔௟
𝜇 ∙ (𝑒
ఓ∆௧ − 1)
 
where  
µμ = specific  growth  rate =
1
𝑡
∙ 𝑙𝑛 ൬
𝑋௙௜௡௔௟
𝑋௜௡௜௧௜௔௟
൰ 
 
 
and X is cell number and t is time in hours. For  µ  of  0  (specific  growth  rate  of  0),  α  was  
calculated using the following equation: 
 
α =
[௠௘௧௔௕௢௟௜௧௘]೔೙೔೟೔ೌ೗ି[௠௘௧௔௕௢௟௜௧௘]೑೔೙ೌ೗
௑∙∆௧
. 
 
Metabolite extraction and analysis  
For metabolite analysis using gas chromatography/mass spectrometry, cells were 
cultured for ~72 h in in glucose- and glutamine-free DMEM-based MEF media with 
dialyzed FBS and the appropriate tracer added.  [U-13C6]glucose, [U-13C5]glutamine, 
and [5-13C]glutamine were all from Cambridge Isotopes Laboratories, Inc.  
 
Cell cycle analysis 
Cells were fixed in ice cold ethanol at 4°C overnight, washed twice in PBS with 1% 
BSA, treated with RNase, and resuspended in propidium iodide buffer to a final 
concentration of 50 µg∙ml-1. Cells were analyzed on a Becton Dickinson FACScan flow 
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cytometer. To assay for new DNA synthesis, the Click-iT EdU Alexa Fluor 488 kit was 
used with 3 hour exposure of cells to 10 µM EdU (Invitrogen C35002), and imaged on a 
Nikon Eclipse TE2000-U microscope with a 4 second exposure time and analyzed using 
the ImageJ software. Cells were dual stained for DNA content and new DNA synthesis 
with the Click-iT EdU Alexa Fluor 488 Kit and FxCycle Violet Stain (Life Technologies F-
10347), respectively, and analyzed on a BD FACSCanto II using FACS Diva software. 
Viability was assessed by propidium iodide dye exclusion using a BD FACScan flow 
cytometer. 
 
Measurement of cell mass and volume 
Dry mass of single cells was measured as previously described (Feijo Delgado et al., 
2013). Briefly, cells were resuspended in 1x PBS and loaded into a 15x20 µm cross-
section suspended microchannel resonator. The buoyant mass of each cell was 
measured first in 1x PBS and then in 1x D2O-PBS. Each experiment was conducted for 
approximately 1.5 h at room temperature. For measurement of cell dry weight from 
batch culture, 106 cells were captured onto membrane filters, dried at 37°C for several 
days and weighed using an analytical balance. Weights of control membrane filters 
loaded only with PBS before drying was subtracted to obtain the weight of 106 cells. Cell 
volumes were measured using a Coulter counter. 
 
DNA strand labeling 
Cells were incubated in medium containing 100 µM CldU (Sigma Aldrich C6891) for 20 
min, washed with PBS, and then incubated in medium containing 250 µM IdU (Sigma 
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Aldrich I7125) for 20 min. Following trypsinization, labeled cells were resuspended in 
PBS with tenfold excess of unlabeled cells and 2.5 µL were transferred to a glass slide 
with 7.5 µL of spreading buffer (200 mM Tris-HCl pH 7.5, 50 mM EDTA, .5% SDS). 
Slides were dried and fixed in cold 3:1 methanol:acetic acid for 2 min. Following a 30 
min treatment with 2.5 N HCl to denature the DNA, slides were washed with PBS and 
blocked at 37 ºC with PBST + 2% BSA. The samples were then incubated at 37 ºC for 1 
hr in PBST + 1% BSA containing primary antibodies to CldU (AbD Serotec OBT0030) 
and IdU (BD 347580), washed with PBST, and incubated at 37 ºC for 30 min in PBST + 
1% BSA containing secondary antibodies conjugated to Cy3 (Jackson 
Immunochemicals 712-165-153) and Alexa Fluor 488 (Jackson Immunochemicals 715-
545-151) with minimal cross-reactivity to mouse and rat IgG, respectively. Samples 
were imaged using the DeltaVision Elite imaging system (Applied Precision) and 
microscope (model IX-71; Olympus) with a 100x objective lens, and the CoolSNAP HQ2 
camera (Photometrics). 
 
Accession Number 
Gene Expression Omnibus GSE60499. 
 
SUPPLEMENTAL INFORMATION 
Supplemental information includes seven figures, two tables, Supplemental 
Experimental Procedures, and the description of the flux model with the complete flux 
data provided as an Excel spreadsheet. 
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FIGURE LEGENDS 
Figure 1. PKM2 deletion with PKM1 expression results in proliferation arrest.  
(A) The effect of 4-OHT treatment on pyruvate kinase isoform expression in PKM2fl/fl 
Cre-ER MEFs was assessed by Western blot analysis. PKM2fl/fl Cre-ER MEFs were 
treated with 4-OHT (PKM2Δ/Δ Cre-ER) or vehicle (PKM2fl/fl Cre-ER) for the indicated 
number of days. Muscle or H1299 cancer cell lysate were included as control samples 
that express only PKM1 or PKM2, respectively.  
(B) Proliferation of PKM2fl/fl Cre-ER MEFs following vehicle (PKM2fl/fl Cre-ER) or 4-OHT 
(PKM2Δ/Δ Cre-ER) treatment was assessed by counting cell numbers as shown.   
(C) Proliferation of Cre negative PKM2fl/fl MEFs treated with vehicle or 4-OHT was 
assessed by counting cell numbers as shown.  
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(D) Western blot analysis of MEFs generated from PKM2fl/+ Cre-ER mice. 4-OHT 
treatment results in PKM2fl/Δ  MEFs that express both PKM2 and PKM1 protein. Western 
blot analysis of 100 ng of recombinant PKM1 or PKM2 (rPKM1, rPKM2) are included as 
controls.  
(E) Proliferation of PKM2fl/+ Cre-ER MEFs treated with vehicle (PKM2fl/+) or with 4-OHT 
(PKM2Δ/+) was assessed by counting cell numbers as shown.  
(F) Proliferation of wildtype MEFs treated with vehicle or 1 µM of PKM2 activator TEPP-
46 was assessed by counting cell numbers over time as shown.  
All data are displayed as means ± SEM, n=3.  
See also Figure S1. 
Figure 2. PKM2Δ/Δ cells undergo cell cycle arrest.  
(A) Quantification of cell viability by propidium iodide staining after treatment of PKM2fl/fl 
MEFs with vehicle (PKM2fl/fl) or 4-OHT (PKM2Δ/Δ). Data are displayed as means ± SEM, 
n=3.  
(B) Classical cell senescence was assayed by acid stable β-galactosidase activity. The 
top panels (labeled Early passage) assess acid  stable  β-galactosidase activity in 
PKM2fl/fl and PKM2Δ/Δ MEFs 9 days after vehicle or 4-OHT treatment, respectively. 
Bottom panels (labeled Late passage) assess acid  stable  β-galactosidase activity in 
PKM2fl/fl and PKM2Δ/Δ MEFs after 12 days in culture. The PKM2fl/fl MEFs had undergone 
proliferation arrest at this time point.  
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(C) Population doublings over 12 days for myoblasts isolated from three different 
PKM2fl/fl Cre-ER mice that were treated with vehicle (PKM2fl/fl) or 4-OHT (PKM2Δ/Δ). 
Data are displayed as means ± SEM, n=3.  
(D) Images of myoblasts generated from PKM2fl/fl Cre-ER mice 9 days after treatment 
with vehicle (PKM2fl/fl) or 4-OHT (PKM2Δ/Δ) are shown. PKM2fl/fl myoblasts induced to 
differentiate by culture in low-serum for 9 days are also presented (right panel).  
(E) EdU uptake of PKM2fl/fl and PKM2Δ/Δ MEFs was measured in PKM2fl/fl Cre-ER MEFs 
7 days after vehicle or 4-OHT treatment. Data are displayed as means ± SEM, n=3.  
(F) DNA content was assessed using propidium iodide staining and flow cytometry in 
PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after PKM2fl/fl Cre-ER MEFs were treated with 
vehicle or 4-OHT.  
(G) DNA content was assessed following dual staining with FxCycle Violet and EdU 
using flow cytometry in PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after PKM2fl/fl Cre-ER MEFs 
were treated with vehicle or 4-OHT.  
See also Figure S2. 
 
Figure 3. PKM2Δ/Δ cells remain metabolically active and are larger than PKM2fl/fl 
cells.  
(A) Glucose uptake rates; (B) lactate excretion rates; (C) the relative production of 14C-
labeled CO2 from uniformly 14C-labeled glucose; (D) average cell volumes; (E) total 
protein content; and (F) single cell dry mass of PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after 
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treatment of PKM2fl/fl MEFs with vehicle or 4-OHT. All data are displayed as means ± 
SEM, n=3 (*p < 0.0001). 
See also Figure S3. 
 
Figure 4. Pyruvate kinase isoform expression affects the use of specific 
metabolic pathways.  
(A) Labeling of intracellular metabolites with [U-13C]glucose or (B) [U-13C]glutamine was 
measured using mass spectrometry in PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after 
PKM2fl/fl Cre-ER MEFs were treated with vehicle or 4-OHT. Complete isotopomer 
distributions used to calculate these values are included in Table S1. The y-axis for all 
graphs in (A) is the calculated percent total glucose contribution (Fendt et al., 2013a).  
See also Figure S4. 
 
Figure 5. Nucleotide deficiency is limiting for proliferation of PKM2Δ/Δ MEFs.  
(A) Pool sizes of intracellular nucleotides in PKM2fl/fl and PKM2Δ/Δ MEFs were 
measured 7 days after PKM2fl/fl Cre-ER MEFs were treated with vehicle or 4-OHT. Pool 
sizes of intracellular nucleotides in PKM2Δ/Δ MEFs supplemented with 250 µM thymine 
were also measured 7 days after 4-OHT treatment. Data are displayed as means ± 
SEM, n=4.  
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(B) Dynamic labeling of intracellular metabolites with [U-13C]glucose and [U-
13C]glutamine was measured using mass spectrometry in PKM2fl/fl and PKM2Δ/Δ MEFs 7 
days after PKM2fl/fl Cre-ER MEFs were treated with vehicle or 4-OHT. The complete 
isotopomer distributions for all measurements are included in Table S2.  
(C) Metabolic fluxes of central carbon metabolism in PKM2fl/fl and PKM2Δ/Δ MEFs. 
Fluxes were modeled based on dynamic and steady state [U-13C]glucose and [U-
13C]glutamine labeling data. With the exception of NTP and lactate, biomass and 
extraction fluxes are not depicted (see supplement for complete flux model). Significant 
differences (>40%, based on 95% confidence interval) between fluxes of PKM2fl/fl and 
PKM2Δ/Δ MEFs are highlighted in grey.  
See also Figure S5, Supplemental Experimental Procedures, and 13C-Metabolic 
flux analysis model. 
 
Figure 6. Genome-scale gene expression analysis reveals no correlation between 
gene expression and proliferation arrest of PKM2Δ/Δ cells.  
(A) Unsupervised hierarchical clustering of PKM2fl/fl and PKM2Δ/Δ MEF expression 
profiles. RNA was isolated from PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after PKM2fl/fl Cre-
ER MEFs were treated with vehicle or 4-OHT.  MEFs were generated from two 
independent PKM2fl/fl Cre-ER MEFs. RNA was analyzed using an Affymetrix GeneChip 
Mouse Gene 1.0 ST array. 
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(B) Unsupervised hierarchical clustering of PKM2fl/fl and PKM2Δ/Δ MEF expression 
profiles for genes involved in nucleotide metabolism. 
See also Figure S6. 
 
Figure 7. Thymine supplementation restores proliferation of PKM2Δ/Δ MEFs.  
(A) Population doublings over 10 days of PKM2fl/fl and PKM2Δ/Δ MEFs were measured 
with or without the indicated metabolites supplemented in the media at a concentration 
of 250 μM. Data are displayed as means ± SEM, n=3. *Population doubling is 
statistically significant (p < 0.05) when compared to the population doubling of PKM2Δ/Δ 
MEFs without any supplements. 
(B) Three representative images of DNA strands incorporating CldU (red) and IdU 
(green) from PKM2fl/fl and PKM2Δ/Δ MEFs five days after PKM2fl/fl Cre-ER MEFs were 
treated with vehicle or 4-OHT are shown; scale bar = 15 µm.  
(C) Quantitation of the percentage of DNA strands incorporating both CldU and IdU is 
shown. For this analysis 237 strands from PKM2fl/fl MEFs and 54 strands from PKM2Δ/Δ 
MEFs prepared as described in (B) were evaluated.  
See also Figure S7.  
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Figure S1.  Proliferation arrest in MEFs isolated from different mice, related to 
Figure 1.  
(A)  Population doublings over 10 days of PKM2Δ/Δ MEFs generated from five different 
PKM2fl/fl Cre-ER mice following vehicle or 4-hydroxytamoxifen (4-OHT) treatment of 
PKM2fl/fl MEFs.  Data are displayed as means ± SEM, n=3 (*p < 0.05).  
(B)  Western blot analysis of Cre negative PKM2fl/fl MEFs following vehicle or 4-OHT 
treatment.  Western blots of lysate from mouse muscle or H1299 cancer cells are 
included as controls for PKM1 and PKM2 expression, respectively.   
(C)  Population doublings over 10 days of MEFs generated from PKM2+/+ Cre-ER mice 
following vehicle, 4-hydroxytamoxifen (4-OHT), or 4-OHT plus 250 µM thymine 
supplementation. PKM2Δ/Δ MEFs generated from PKM2fl/fl Cre-ER mice following 4-OHT 
treatment are also shown for comparison.  Data are displayed as means ± SEM, n=3.   
(D)  Western blot analysis of MEFs generated from PKM2+/+ Cre-ER mice.  4-OHT 
treatment does not affect pyruvate kinase isoform expression.  Western blot analysis of 
100 ng of recombinant PKM1 or PKM2 (rPKM1, rPKM2) are included as controls.   
(E)  Western blot analysis of MEFs generated from PKM2+/+ Cre-ER mice with vehicle 
or 4-OHT treatment.  Irradiated MEFs are included as controls.   
(F)  Population doublings over 10 days of wildtype MEFs with pLHCX vector only or with 
exogenous expression of PKM1 cDNA.   Data are displayed as means ± SEM, n=3 (*p 
< 0.05).   
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Figure S2.  PKM2Δ/Δ cells undergo proliferation arrest without cell death or 
differentiation, and the arrest is different from cell cycle arrest triggered by 
nutrient deprivation, related to Figure 2.  
(A) Quantification of cell death over a 24 h period by LDH release after treatment of 
PKM2fl/fl MEFs with vehicle (PKM2fl/fl) or 4-OHT (PKM2Δ/Δ).  Data are displayed as 
means ± SEM, n=3. 
(B) Oil Red O staining of PKM2fl/fl and PKM2Δ/Δ MEFs 6 days after treatment with 
vehicle or 4-OHT.  The right pane shows a positive control of wildtype immortalized 
MEFs differentiated into adipocytes by expression of PPARγ. 
(C) Western blot analysis of PKM2fl/fl and PKM2Δ/Δ myoblasts 9 days after treatment with 
vehicle or 4-OHT.   
(D) Western blot analysis of primary myoblasts following incubation in low-serum media 
to induce differentiation into myotubes. Western blot analysis of 100 ng of recombinant 
PKM1 or PKM2 (rPKM1, rPKM2) are included as controls for both panels. 
(E) Population doublings over 10 days of MEFs generated from wildtype mice in regular 
DMEM media or DMEM media without lysine.  Data are displayed as means ± SEM, 
n=3 (*p < 0.05). 
(F) DNA content was assessed using propidium iodide staining and flow cytometry in 
PKM2fl/fl MEFs, PKM2Δ/Δ MEFs, and MEFs cultured in media without lysine.  
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Figure S3.  Levels of intracellular fatty acids, related to Figure 3.  Fatty acids were 
extracted from PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after treatment of PKM2fl/fl MEFs 
with vehicle or 4-OHT.  All data are displayed as means ± SEM, n=3 (*p < 0.05).   
 
                                                                            
 
 
 
Figure S4.  Less palmitate is synthesized from glucose and glutamine in PKM2Δ/Δ 
MEFs relative to PKM2fl/fl MEFs, related to Figure 4.  The relative contribution of [U-
13C]glucose, [U-13C]glutamine, and [5-13C]glutamine to newly synthesized palmitate in 
PKM2fl/fl and PKM2Δ/Δ MEFs 7 days after PKM2fl/fl Cre-ER MEFs were treated with 
vehicle or 4-OHT was determined as described previously (Fendt et al., 2013; Metallo et 
al., 2012).  Data are displayed as means ± SEM, n=3 (*p < 0.05).  
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Figure S5.  Pyruvate kinase isoform expression affects cellular metabolism, 
related to Figure 5. 
(A) Profiles of intracellular metabolites in PKM2Δ/Δ MEFs without or with 250 µM thymine 
supplementation 7 days after treatment of PKM2fl/fl MEFs with vehicle or 4-OHT, as 
determined by GC-MS or LC-MS/MS.  Relative levels are expressed as the log ratio of 
the normalized signal intensity in PKM2Δ/Δ MEFs to the normalized signal intensity in the 
PKM2fl/fl MEFs.  Signal intensity was also normalized by total protein content to account 
for the difference in size between PKM2fl/fl and PKM2Δ/Δ MEFs (n=3).   
(B) Net serine to glycine and THF flux in PKM2fl/fl and PKM2Δ/Δ MEFs. Fluxes were 
modeled based on 13C glucose labeling in serine and glycine and the serine and glycine 
uptake rates. Differences between PKM2fl/fl and PKM2Δ/Δ MEFs are not significant 
based on 95% confidence intervals. 
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Figure S6.  Expression analysis of select genes and proteins, related to Figure 6.   
(A) Quantitative RT-PCR results for genes identified to have the largest difference in 
gene expression from analysis using Affymetrix GeneChip Mouse Gene 1.0 ST array:  
Interferon Induced Protein 44 (IFI44); Interferon-Induced Protein With Tetratricopeptide 
Repeats 1 (IFIT1); Hemicentin 1 (HMCN1).  RNA was isolated from PKM2fl/fl and 
PKM2Δ/Δ MEFs derived from four independent PKM2fl/fl Cre-ER embryos 7 days 
following vehicle or 4-OHT addition.  Data are displayed as means ± SEM, n=3. 
(B) Western blot analysis of protein lysates from PKM2fl/fl and PKM2Δ/Δ MEFs derived 
from three independent PKM2fl/fl Cre-ER embryos for enzymes involved in nucleotide 
biosynthesis: thymidylate synthase (TS); Glucose-6-phosphate dehydrogenase (G6PD).  
PKM2fl/fl Cre-ER MEFs were treated with 4-OHT (PKM2Δ/Δ) or vehicle (PKM2fl/fl) for 7 
days before collecting protein lysates. 
(C) Quantitative RT-PCR results for genes involved in nucleotide biosynthesis: 
Carbamoyl-Phosphate Synthetase 2, Aspartate Transcarbamylase, and Dihydroorotase 
(CAD); Glucose-6-Phosphate Dehydrogenase (H6PD); Phosphoribosyl Pyrophosphate 
Amidotransferase (PPAT); Transketolase (TKT).  RNA was isolated from PKM2fl/fl and 
PKM2Δ/Δ MEFs derived from four independent PKM2fl/fl Cre-ER embryos 7 days 
following vehicle or 4-OHT addition.  Data are displayed as means ± SEM, n=3. 
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Figure S7. Exogenous thymine supplementation affects PKM2Δ/Δ, but not PKM2fl/fl, 
MEF proliferation, related to Figure 7.   
(A) Population doublings over 10 days of PKM2fl/fl MEFs were measured with or without 
thymine supplemented in the media at a concentration of 250 μM.  Data are displayed 
as means ± SEM, n=3.   
(B) Population doublings over 10 days of PKM2fl/fl and PKM2Δ/Δ MEFs.  250 μM thymine 
was added on day 5 after addition of 4-OHT when PKM2Δ/Δ MEFs had stopped 
proliferating.  All proliferation of PKM2Δ/Δ MEFs occurred between day 5 and 10 after 
thymine addition. Data are displayed as means ± SEM, n=3.  *The difference in 
population doubling of PKM2Δ/Δ MEFs with and without thymine supplementation is 
statistically significant (p < 0.05). 
 
 
 
  
 
 
Table S1 included as Excel spreadsheet. Mass isotopomer distributions (MIDs) of 
measured intracellular metabolites, related to Figure 5.   MIDs of all metabolites 
were measured by GCMS, except for MIDs of UMP and hexose phosphate, which were 
measured by LC-MS/MS.  Numbers shown are average fraction of each isotopomer ± 
SEM, n=3.  MIDs have been corrected for natural isotope abundance.    
 
 
 
Table S2 included as Excel spreadsheet.  Mass isotopomer distributions (MIDs) of 
measured intracellular metabolites over time, related to Figure 5.   MIDs of all 
metabolites were measured by LC-MS/MS.  Numbers shown are average fraction of 
each isotopomer ± SEM, n=3.  MIDs have been corrected for natural isotope 
abundance.     
 
 
SUPPLEMENTAL EXPERIMENTAL PROCEDURES 
 
All mouse studies were performed in accordance with institutional guidelines and 
approved by the MIT committee on animal care. 
 
Isolation and culture of primary mouse embryonic fibroblasts  
Primary mouse embryonic fibroblasts (MEFs) were isolated and cultured using an 
adaption of previously published methods (Springer et al., 2001). Embryos were 
isolated from the uterus of pregnant mice staged E11.5 – E14.5 of gestation and 
decapitated in PBS. Each embryo was processed separately due to heterogeneity in 
genetic background. After removing blood and organ tissue from each embryo, each 
was homogenized, resuspended in 2 ml of 0.25% warm trypsin, and incubated at 37°C 
for 30 min. To break up genomic DNA, 5 ml of HBSS with CaCl2 and MgCl2 was first 
added to each tube, and treated with 5 µl of 5µg∙µl-1 DNase. The mixture was incubated 
at 37°C for 5 - 15 min. The supernatant was collected and transferred to a fresh tube on 
ice. Additional 2 ml of 0.25% trypsin was added to the remaining tissue pieces and 
incubated at 37°C for 30 min and again treated with HBSS and DNase. The supernatant 
was collected and added to the previous tube of cells on ice. Cells were pelleted, 
resuspended  in  MEF  medium  (Dulbecco’s  Modified  Eagle’s  Medium  with  10%  heat  
inactivated FBS, 1% streptomycin/penicillin, 1 mM glutamine, and 0.1 mM 2-
mercaptoethanol) and plated at a density of 5 × 106 cells per 10 cm plate. Cells were 
split before reaching confluence and replated at 750,000 cells per 10 cm plate, or frozen 
in 3 × 106 cell aliquots. 1 µM 4-hydroxytamoxifen dissolved in ethanol was used to 
induce recombination of PKM2fl alleles. Cells starved of lysine were incubated in lysine-
free DMEM and doubling time analyzed over 10 days. 
 
Isolation and culture of primary myoblasts 
Primary myoblasts were isolated and cultured using an adaptation of previously 
published methods (Rando and Blau, 1994; Springer et al., 2001).  Muscle was isolated 
from 2 – 2.5 week old mice and mechanically disaggregated, followed by enzymatic 
disaggregation with Collagenase P (10 mg∙ml-1 in PBS; Roche) at 37°C for 45 min with 
trituration every 15 min.  The slurry was passed through a 70µm filter, and additional 
PBS was added to dilute out collagenase.  Cells were pelleted by centrifugation and 
pre-plated on a non-treated tissue culture plate for 4 h to remove fibroblasts.  
Unattached myoblasts were re-plated in 0.1% gelatin coated plates in F-10-based 
primary   myoblast   growth   medium   (Ham’s   F10   medium   with   10%   Cosmic   calf   serum  
(Hyclone), 1% streptomycin/penicillin, 1 mM glutamine, and 2.5 ng∙ml-1 basic fibroblast 
growth factor (PeproTech)).  Medium was changed every 2 days, and cells were split 
before reaching confluence, at no more than 1:5 dilution.  Myoblasts are capable of 
differentiation into myotubes when cultured under conditions that promote differentiation 
(Springer et al., 2001).  For differentiation into myotubes, cells were cultured in low-
serum   medium:      Dulbecco’s   Modified   Eagle’s   Medium   with   5%   horse   serum,   1%  
streptomycin/penicillin, and 1 mM glutamine.  Medium was changed daily.  To prepare 
gelatin coated plates, 2% gelatin stock (Sigma-Aldrich) was warmed up to 37°C and 
diluted to a concentration of 0.1% in PBS.  Approximately 7 ml of the diluted 0.1% 
gelatin solution in PBS was added to each 10 cm plate and incubated at 37°C for at 
 
 
least 1 h.  The gelatin solution was aspirated, and plates were rinsed with fresh PBS 
before use. 
 
Cell lysis and immunoblotting 
Cell lysis and Western blot analysis were carried out according to standard protocols.  
The following dilutions of primary commercial antibodies were used as probes: 1:20000 
dilution of anti-PKM1 (Sigma SAB4200094); 1:10000 dilution of anti-PKM2 (Cell 
Signaling 4053S); 1:500 dilution of anti-actin (Abcam ab8226); 1:1000 dilution of anti-γ-
H2AX (EMD Millipore 05-636); 1:1000 dilution of anti-TS (Cell Signaling 9045); and 
1:1000 dilution of anti-G6PD (Cell Signaling 12263).  Primary antibodies were diluted in 
5% BSA containing 0.1% azide and incubated overnight at 4°C.  Secondary antibodies 
were diluted in 5% BSA at a dilution of 1:10000. 
 
Cell cycle analysis 
Cells were centrifuged at 1000g for 5 minutes and washed twice in PBS. The cell pellet 
was resuspended in 500 µl of ice-cold PBS. To fix the cells, 5 ml of ice cold ethanol was 
added to the cell suspension. Cells were fixed at 4°C at least overnight. Just before 
analysis, fixed cells were centrifuged at 1000g and washed twice in PBS with 1% BSA. 
Cells were treated with RNase and resuspended in the wash buffer with propidium 
iodide added to a final concentration of 50 µg∙ml-1. Cells were analyzed for propidium 
iodide (JM-1056,  from  MBL  Int’l.)  content  on  a  Becton  Dickinson FACScan flow 
cytometer; a laser with wavelength 488 nm was used for excitation and emission 
measured at 585 nm. To assay for new DNA synthesis, the Click-iT EdU Alexa Fluor 
488 kit was used (Invitrogen C35002). 10 µM of EdU was used for a 3 hour incubation. 
Cells were imaged on a Nikon Eclipse TE2000-U microscope with a 4 second exposure 
time and analyzed using the ImageJ software. Cells were dual stained for DNA content 
and new DNA synthesis with the Click-iT EdU Alexa Fluor 488 Kit and FxCycle Violet 
Stain (Life Technologies F-10347), respectively, and cells were analyzed on the BD 
FACSCanto II using FACS Diva software. Viability was assessed by propidium iodide 
dye exclusion. Trypsinized cells were resuspended in PBS + 1% BSA with 2 µg/mL 
propidium iodide and analyzed using a BD FACScan. 
 
Senescence-associated  β-galactosidase staining and LDH assay for cell death 
Cells were plated at a density of 125,000 cells per well of 6-well plates on day 0 with 
vehicle or 4-OHT treatment.  At indicated days following seeding, senescence-
associated   β-galactosidase activity was detected using previously described methods 
(Debacq-Chainiaux et al., 2009).  LDH was measured using the Roche Cytotoxicity 
Detection Kit (Roche 11644793001).  
 
Metabolite extraction and analysis  
For metabolite analysis using gas chromatography/mass spectrometry, cells were 
cultured for ~72 h in 6-well plates in glucose- and glutamine-free DMEM (Sigma D5030) 
containing 10% dialyzed FBS, 1% streptomycin/penicillin, 4 mM glutamine or 25 mM 
glucose, and the appropriate tracer, [U-13C6]glucose, [U-13C5]glutamine, or [5-
13C]glutamine (all from Cambridge Isotopes Laboratories, Inc).  After incubation, media 
was aspirated, and each well was rinsed with 1 ml ice-cold saline.  Saline was 
aspirated, and cells were quenched with 500 µl of -20°C HPLC-grade methanol.  300 µl 
 
 
of ice-water was added, and cells were scraped with a 1000 µl pipette tip and collected 
in 1.5 ml Eppendorf tubes.  500 µl of -20°C chloroform was added to each tube and 
vortexed for 10 min at 4°C.  Extracts were centrifuged at 14,000g for 5 min at 4°C.  The 
upper aqueous phase was collected in a separate tube evaporated under nitrogen for 
polar metabolite analysis.  The lower layer was collected in a separate tube and 
evaporated under nitrogen for nonpolar metabolite analysis.  Metabolites were 
derivatized and analyzed using gas chromatography/mass spectrometry as previously 
described (Fendt et al., 2013; Metallo et al., 2012). The rate of fatty acid synthesis was 
calculated as previously described (Fendt et al., 2013). 
 
For metabolite analysis using liquid chromatography tandem mass spectrometry (LC-
MS/MS), cells were cultured for ~24 h in 10 cm plates.  After incubation, media was 
aspirated, and each plate was rinsed with 10 ml ice-cold saline.  Saline was aspirated, 
and cells were quenched with 2.89 ml of -20°C HPLC-grade methanol.  1.74 ml of ice-
water was added, and cells were scraped with a cell lifter and collected in 15 ml conical 
tubes.  2.89 ml of -20°C chloroform was added to each tube and vortexed for 10 min at 
4°C.  Extracts were centrifuged at 4,000g for 15 min at 4°C.  The upper aqueous phase 
was collected in a separate tube evaporated under nitrogen for polar metabolite 
analysis.  LC-MS/MS analysis was done using a variation of the method described 
previously (Munger et al., 2008).  A Paradigm MS4 HPLC (Michrom Bioresources, 
Auburn, CA), and a Synergi Hydro column (4 µm particle size, 80 Å, 150 mm × 2 mm, 
from Phenomenex) were used for separation of metabolites by polarity.  Prior to column 
separation, samples were loaded onto a trapping column (C18, 4 mm × 2 mm, from 
Phenomenex) and washed for 30 seconds with HPLC grade water containing 10 mM 
tributylamine and 15 mM acetic acid for rapid desalting.  HPLC separation was coupled 
with negative-mode electrospray ionization (ESI) to a TSQ Vantage Triple Stage 
Quadrupole Mass Spectrometer (Thermo Scientific) operating in multiple reaction 
monitoring (MRM) mode.  The LC parameters were as follows: autosampler 
temperature, 10 ºC; injection volume, 10 µl; column temperature, room temperature; 
and flow rate, 200 µl∙min-1. The LC solvents were Solvent A: 10 mM tributylamine and 
15 mM acetic acid in 97:3 water:methanol (pH 4.95); and Solvent B: methanol.  Elution 
from the column was performed over 50 min with the following gradient:  t = 0, 0% B; t = 
5, 0% B; t = 10, 20% B; t = 20, 20% B; t = 35, 65% B; t = 38, 95% B; t = 42, 95% B, t = 
43, 0% B; t = 50, 0% B.  ESI spray voltage was 3,000 V.  Nitrogen was used as the 
sheath gas at 30 psi and as the auxiliary gas at 10 psi, and argon as the collision gas at 
1.5 mTorr, with the capillary temperature at 325 ºC. Scan time for each MRM transition 
was 0.1 s with a scan width of 1 m/z.  The LC runs were divided into time segments, 
with the MRM scans within each time segment containing compounds eluting during 
that time interval. For compounds eluting near boundaries between time segments, the 
MRM scan corresponding to the compound was conducted in both time segments. 
Instrument control, chromatographic control, and data acquisition were performed by 
the Xcalibar software (Thermo Scientific).   
 
Data analysis was performed using MAVEN (Clasquin et al., 2012; Melamud et al., 
2010).  Pool sizes were first normalized by total protein of extracted cells.  The protein 
content of extracted cells was determined from the dried protein fraction from each 
extraction, which was incubated overnight in 2 ml of 0.2 M KOH, and quantified by 
 
 
Bradford assay.  Isotope labeling data was corrected for the natural abundance of 
different isotopes using IsoCor (Millard et al., 2012). 
 
CO2 production from glucose 
To assay 14CO2 production from 14C-labeled  glucose,  cells  were  incubated  in  5  μCi∙ml-1 
uniformly labeled (American Radiolabeled Chemicals #0122A) glucose for 24 hours. 
Carbon dioxide was trapped on a tight-fitting piece of Whatman paper that had been 
saturated with a solution of Ba(OH)2; the resulting reaction between emitted CO2 and 
Ba(OH)2 resulted in a barium bicarbonate precipitate that was retained on the paper. 
The paper overlying each well was counted in 10 ml of scintillation fluid using a 
Beckman Coulter LS6500 Scintillation Counter. Total 14CO2 emission was calculated by 
subtracting background radioactivity from the radioactivity on the filter paper.  
 
Exogenous PKM1 expression 
Standard retroviral infection protocol was used to introduce PKM1 expression 
constructs or delivery of an empty vector control (pLHCX). Briefly, target cells were 
incubated in virus-containing media produced from an HEK-293T packaging line for 24 
hours. Media was changed and the cells were allowed to recover in standard media for 
24  hours  before  they  were  incubated  with  hygromycin  (100  μg/mL)  for  5  days  with  daily 
media changes. During antibiotic selection and proliferation analysis, cells were 
passaged to a confluence of 750,000 cells per 10 cm plate every 3 days. 
 
Gene expression analysis 
Primary MEFs derived from two independent embryos were treated with vehicle or 4-
OHT treated as previously described.  The growth medium was removed 7 days 
following vehicle or 4-OHT addition, and cells were lysed on the dish using TRIzol 
Reagent   (Life   Technologies);;   RNA   was   isolated   according   to   the   manufacturer’s  
protocol and RNA pellets were resuspended in DEPC-treated water.  Microarray 
analysis was performed by the MIT BioMicro Center.  Briefly, RNA quantity and quality 
were determined using an Agilent 2100 BioAnalyzer prior to sample preparation and 
hybridization to an Affymetrix GeneChip Mouse Gene 1.0 ST array.  The intensity 
(.CEL) files were RMA normalized using Affymetrix Expression Console. Unsupervised 
hierarchical clustering was performed with Cluster 3.0. Genes were filtered based on 
standard deviation. Genes and arrays were centered at the mean prior to clustering 
genes and arrays using complete linkage methods and the correlation (uncentered) 
similarity metric.  Probe identifiers were converted to gene names using DAVID (Huang 
et al., 2008, 2009). Clustering results were visualized with JavaTreeView. Figures were 
converted to a full-spectrum color scale using Matlab. Fold change analysis was 
conducted using Significance Analysis of Microarrays tool (Tusher et al., 2001) featured 
in the MuliExperiment Viewer within the TM4 Microarray Software Suite (Saeed et al., 
2003).  Microarray data are available on Gene Expression Omnibus (GEO), accession 
number GSE60499. 
 
 
Retroviral Infection  
A standard retroviral infection protocol was used to introduce expression constructs for 
PKM1 or an empty vector control (pLHCX). Briefly, HEK-293T cells were incubated for 
 
 
36  hours  in  media  containing  3  μg  of  the  EcoPak  packaging  DNA  and  3  μg  of  the  vector  
of interest. Target cells were then incubated in the virus-containing media for 24 hours. 
Media was changed and the cells were allowed to recover in standard media for 24 
hours   before   they  were   incubated  with   hygromycin   (100  μg/mL)   for   5   days  with   daily  
media changes. During antibiotic selection and proliferation analysis, cells were 
passaged to a confluence of 750,000 cells per 10 cm plate every 3 days. 
 
RNA  
RNA was isolated from PKM2fl/fl and PKM2Δ/Δ MEFs derived from PKM2fl/fl Cre-ER 
embryos 7 days following vehicle or 4-OHT addition using the Qiagen RNeasy Mini Kit 
(Qiagen 74104). Quantitative RT-PCR was performed using the QuantiTect SYBR 
Green RT-PCR kit (Qiagen 204243). Primer sequences for RT-PCR were the following: 
 
Actin-F: CATCATGCGTCTGGACCTG  
Actin-R: CTCACGTTCAGCTGTGGTCA 
 
CAD-F: CGTGGAGACCATTGAACTGA 
CAD-R: GCCTGAGCCTGTTCAAGAGA 
 
CPT1-F: TCAAGAATGGCATCATCACTG 
CPT1-R: GGAGGGGTCCACTTTGGTAT 
 
H6PD-F: GCAGGTGTCCTTGTCCACAT 
 H6PD-R: ACGCCCGATTCTTAAACACA 
 
HMCN1-F: TGTGAATGAAGATGCTGGTGA 
HMCN1-R: TTCCACTGGCTCAAGAGTGA 
 
IFI44-F: AACATGGCATTCTGCATTTG 
IFI44-R: AATGCCTCCAGCTTGGACTT 
 
IFIT1-F: ATGGGAGAGAATGCTGATGG 
IFIT1-R: GAGATTCTCACTTCCAAATCAGG 
 
PPAT-F: GAAGACCAAATGGTTTATACAGTAAGG 
PPAT-R: CAGGCGTAGCAGACTCTGGA 
TKT-F: TCACAGGGATTGAAGACAAGG 
TKT-R: GGCCAGGATCTTCTTTTTGC. 
 
Statistical analyses 
Data are presented as means ± standard error of the mean (SEM).  All P values were 
obtained using an unpaired two-tailed t-test, and statistical significance was determined 
at a value of 0.05. 
13C-Metabolic flux analysis model included as Excel file. 
Intracellular fluxes where modeled with the MatLab based software Metran (Antoniewicz 
et al., 2007; Young et al., 2008). 
 
 
 
The flux model contains the following assumptions: 
x Fluxes were modeled based on intracellular labeling of lactate, alanine, citrate, a-
ketoglutarate, fumarate, malate, aspartate, glutamate, glutamine 
x The system is in steady state. Unpublished data confirm that there is no 
significant difference in the labeling of polar metabolites after 24h or 72h 
x All CO2 in the system is unlabeled 
x Fumarate and succinate have no orientation, because they are symmetrical 
x Any metabolite that is modeled in two different compartments is in equilibrium 
x Entry of unlabeled pyruvate and AcCoA precursors is possible. Which is possible 
due to fatty acid oxidation or entry of amino acids from the media 
x Flux to fatty acids is not constrained 
x 3PG to serine flux was estimated with a specific serine/glycine flux model 
x Biomass fluxes were based on Metallo et al 2009. The biomass fluxes were 
scaled for the total protein content of PKM1 and PKM2 cells and the measured 
growth rates 
x Flux magnitude to NTPs was based on Metallo et al 2009 and scaled by EdU 
incooperation into DNA 
x Pentose phosphate pathway flux was modeled as lower bound based on the flux 
to NTPs 
x Glutamine to glutamate flux was calculated based on dynamic labeling data 
(Yuan et al., 2008).  
 
Specific assumptions for serine/glycine model: 
x Fluxes were modeled based on serine and glycine labeling 
x Metran does not allow constraining net fluxes, therefore a forward flux for 
serine/glycine entry into the cell was modeled, while the reverse flux was 
modeled as serine/glycine sink. The difference of the forward and revers flux is 
the net flux, which was measured as serine/glycine uptake rate. 
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